BACKGROUND: Approaches to pain management are diverse, requiring prescribers to evaluate an array of clinical issues and potential solutions. In addition to the difficult task of selecting a treatment option, pain treatment may be further complicated by multiple prescribers, multiple medications, and multiple mechanisms of pain origination.
A pproaches to pain management are diverse, requiring prescribers to evaluate an array of clinical issues and potential solutions. Treatment options including lifestyle changes, medications, cognitive and physical therapy, surgery, and alternative medicine are weighed in consideration of other patient factors such as age and comorbid conditions. In addition to the difficult task of selecting a treatment option, pain treatment may be further complicated by the use of multiple classes of medications [1] [2] [3] and multiple mechanisms of pain origination. 4 
Complexity of Pain Management Among Patients with Nociceptive
or Neuropathic Neck, Back, or Osteoarthritis Diagnoses pain medication use (i.e., cancer) was removed. The goal was to identify a wide range of patients of the type that might be seen in clinical practice, who had neuropathic or nociceptive neck or back diagnoses.
Patients were included in this analysis if they met all of the following criteria: (a) had continuous insurance eligibility between September 1, 2006 Patients were excluded from the analysis if they met any of the following exclusion criteria: (a) had 1 or more claims indicating a stay in a long-term care or skilled nursing facility (because of concerns about the completeness of their claims data); (b) had a diagnosis for history of alcohol and/or drug abuse; (c) had a pregnancy or pregnancy-related claim during the observation period; (d) had a surgical procedure involving the spine or intervertebral disc prior to the observation period; (e) had a diagnosed malignancy, with the exception of nonmelanoma skin cancers, during or prior to the observation period; (f) had noncommercial coverage; or (g) had invalid or missing data for key analysis variables.
Patients meeting the analysis inclusion and exclusion criteria were assigned to neuropathic and nociceptive neck and back and osteoarthritis cohorts based on the presence of diagnosis codes for 1 of the selected conditions, based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM; Table 1 ). The assigned cohorts were neuropathic-related neck/back diagnoses (NEURO); neuropathic and nociceptive neck/back diagnoses (NEURO/NOCI); nociceptive neck/back diagnoses without a neuropathic-related diagnosis (NOCI); and only osteoarthritis (OA) diagnoses. NOCI, NEURO, and NEURO/NOCI were assigned without regard to coexisting OA diagnoses. See Figure 1 for sample identification.
Statistical Analysis
Categorical variables were summarized using frequencies and percentages. Continuous measures were summarized with means, standard deviations, minimums, maximums, and medians. Comparisons between cohorts were conducted with analysis of variance for continuous measures and chi-square tests for categorical variables. While statistical tests were conducted, we note that there are large and disparate sample In addition to complaints of pain, patients often present with other multiple coexisting chronic diseases. [5] [6] [7] [8] According to the Centers for Disease Control and Prevention, 47% of U.S. adults aged 55 or greater have 2 or more chronic conditions (e.g., arthritis, asthma, cancer, cardiovascular disease, chronic obstructive pulmonary disease, and diabetes). 9 These diseases require chronic treatment, often with multiple medications. Thus, pain treatment is often concurrent with chronic disease treatment in a large number of patients.
There are few published studies that describe the complexity of pain management. This analysis attempts to provide an in-depth description of the potential complexities associated with pain management in terms of patient characteristics, physician involvement, medication variety, and other treatment services used in a large cohort of patients receiving treatment for chronic or acute pain. The goal of the analysis was to raise awareness of the complexity of treating pain with the focus specifically on medications, since medications are a mainstay of pain treatment. Understanding the characteristics of patient populations that might contribute to increased risks for complexity may signal areas that need attention when making medication-prescribing decisions. Factors that may require specific consideration by clinicians when prescribing medications are highlighted.
sizes. In many cases, trivial differences may be statistically significant. The interpretation should rely on differences that are of clinical significance. Given the large number of comparisons, only general comments are made regarding statistical significance. No adjustments were made for multiplicity. SAS/ STAT software for Windows version 9.2 (SAS Institute Inc., Cary, NC) was used for all analyses.
Variable Descriptions
The analysis included the following variables: patient demographics (e.g., age, gender); comorbidities; office visits (e.g., physician, chiropractor, physical therapy, psychiatry, allergist); the percentage of patients with visits to medical providers by specialty and number of different prescribers; the mean number of prescription claims; pain medications as classified by the World Health Organization (WHO) pain ladder; adjuvant medications; adjuvant procedures; and potential drug interactions. All analyses were conducted by cohort. Operational definitions of the key variables are presented in the following sections.
Comorbidities of interest and specific codes are presented in Appendix A (available in online article). Comorbidities were identified from a published article using the ICD-9-CM diagnosis codes and refined based on an analysis by Gore et al. (2011) . 10 The percentage of patients with at least 1 claim during the 2-year observation period with each of the comorbidities was identified.
Office visit counts for the observation period were calculated for the overall group and for each cohort using claims data. The observation period was a fixed 2-year observation period from September 1, 2006, to August 31, 2008.
Most frequently appearing medical providers during the observation period were identified using the Standard Provider field included in the outpatient claims database. Standard Provider is a field provided by the data vendor that describes the provider's specialty. Each uniquely identified provider per patient per date was counted as 1 occurrence. In addition to this more general assessment, prescribing specialties were identified qualitatively from the list of Standard Provider types assigned in order to provide a count from the subset of provider types who regularly prescribe chronic medications to the patients in our analysis. Counts for the number of patients with visits to these providers were provided. Mean prescription claims counts for the entire observation period were calculated and grouped into categories using National Drug Codes. These counts included all of the prescription claims, including new or refill medications. The claims were divided into categories of all prescriptions, pain-related, adjuvant, and nonpain-related prescriptions. Claims count and categories were assessed for each cohort.
The assessment of pain medication was based on the WHO pain ladder. The pain ladder has 3 steps representing mild, moderate, and severe pain. For step 1 (mild pain), nonopioid medications with or without adjuvant analgesic therapy are recommended. Typically, the drugs used at this step are acetaminophen or nonsteroidal anti-inflammatory medications (NSAIDs; e.g., aspirin, ibuprofen, diclofenac).
Step 2 on the was 47.8 years, and females comprised 60.4% ( Table 2 ). The most frequently occurring comorbidities (observed in > 40% of patients) included cardiovascular and neuropathic pain conditions (in the NEURO and NEURO/NOCI groups only; Table  3 ). Hypertension was the most commonly observed specific comorbidity, occurring in more than 60% of OA patients, followed by NEURO (46.9%), NEURO/NOCI (43.6%), and NOCI (35.2%) patients. Hyperlipidemia occurred in 59.5% of OA patients, followed by NEURO (51.6%), NEURO/NOCI (48.9%), and NOCI (41.6%) patients. Depression was observed in 21.3% of NEURO/NOCI patients, followed by NOCI (18.4%), OA (15.8%), and NEURO (15.6%) patients. Diabetes was observed in 22.4% of OA patients, followed by NEURO (19.8%), NEURO/NOCI (15.4%), and NOCI (11.7%) patients. Sleep disturbance was observed in 20.0% of the NEURO/NOCI cohort, followed by OA (18.9%), NEURO (16.6%), and NOCI (16.6%) cohorts. Thyroid disorder was observed in 15% to 19% of the cohorts. If a significant omnibus test (P < 0.05) was found using ANOVA, then pairwise statistical tests were conducted. The results of these tests indicated that differences equal to or larger than the following magnitudes were statistically significant (P < 0.05 or less): NEURO versus NEURO/NOCI 1.5%; NEURO versus NOCI 0.5%; NEURO versus OA 1.6%; NEURO/NOCI versus NOCI 0.2%; NEURO/NOCI versus OA 0.5%; and NOCI versus OA 0.5%.
Office Visits
The mean number of office visits during the observation period for the overall population was 32.0 (standard deviation [SD] 27.9) visits (Table 4 ). The NEURO/NOCI cohort led the office visits with a mean of 38.1 visits (SD 31.3), followed by the NOCI, NEURO, and OA cohorts at 28.4 visits (SD 24.6), 25.1 visits (SD 23.6), and 20.8 visits (SD 18.3) during the 2-year observation period. All pairwise statistical tests were significant at P < 0.0001.
Medical Providers
Overall visits to prescribing specialists indicate that general and family practice (GP/FP) and internal medicine (IM) physicians accounted for the highest percentage of patients with at least 1 visit during the 2-year analysis definition period, ladder (moderate pain) adds the use of a weak opioid (e.g., tramadol, codeine, dihydrocodeine). The third rung (severe pain) adds the use of strong opioids (e.g., morphine, fentanyl, buprenorphine, oxycodone, hydromorphone). The medications included on the rungs of the WHO pain relief ladder are shown in Appendix B (available in online article). Medication availability was defined as the percentage of days where a patient theoretically had access to the drug based on the dispensing dates and days supply. Days of availability for pain ladder classes were categorized into > 0% to < 30%, 30% to < 80%, and ≥ 80%.
Adjuvant treatments may be used at any step on the ladder and include antidepressants, anticonvulsants, steroids, muscle relaxants, exercise, psychological support, temperature therapy, physical therapy, hydrotherapy, and acupuncture. Adjuvant pain medications were categorized using the therapeutic classes and then were refined based on a published list.
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The therapeutic class approach is broader than just the specific pain-related adjuvant treatments; however, use of any drug in the class may affect pain treatment decisions.
Drug interaction potential was also evaluated. Potential drug interactions were defined based on the interaction within the cytochrome P450 system. Pain medications were evaluated both as substrates on which other drugs could act and as inhibitors and inducers that act on other drugs as substrates. Pain medications were assessed for overlapping availability (i.e., based on dispensing dates and days supplies) for a minimum of 10 days based on dispensing dates and days supply of medication (a proxy for concomitant use).
Adjuvant therapies (e.g., chiropractic therapy, physical therapy) also are used to treat pain. Adjuvant therapies were identified using medical codes that are frequently associated with the treatment of pain. These procedures were included to provide a comprehensive view of how pain is treated.
■■ Results Patient Demographics and Comorbidities
The analysis included 85,014 patients, of which 2,375 were classified as NEURO; 37,019 were NEURO/NOCI; 39,496 were NOCI; and 6,124 were OA. The mean age of the overall sample Patient Characteristics highest mean claim count of 64.6 prescriptions (SD 60.1) and was statistically significantly higher than all other cohorts with the exception of the OA cohort (P = 0.3176). Considering only pain-related medications, the overall mean claim count was 8.8 prescriptions (SD 13.0), and the NEURO/NOCI group had the highest mean at 11.0 prescription claims (SD 15.0) during the observation period. All pairwise comparisons of pain medication claim counts between cohorts were statistically significant at P < 0.0001. Considering adjuvant medication claims, the overall mean prescription claim count was 12.7 prescriptions (SD 15.5) during the period and the NEURO/NOCI mean count was the highest at 13.7 prescriptions (SD 16.5). The nonpain-related prescriptions accounted for the highest volume of claims, with the overall mean during the period of 41.2 claims (SD 42.5). In this category, the OA patients accounted for the highest mean number of prescriptions at 48.0 claims (SD 44.5; P < 0.0001 for all pairwise comparisons with the OA cohort).
Weak opioids (WHO pain relief ladder rung 2) accounted for the majority of pain medication claims across all cohorts (Figure 2) . The percentage of patients who had nonopioids (WHO pain relief ladder rung 1), weak opioids (WHO pain relief ladder rung 2), or strong opioids (WHO pain relief ladder rung 3) available (i.e., filled) were similar across cohorts. A greater percentage of NEURO/NOCI and OA patients had nonopioid availability (53.4% and 55.5%, respectively) than patients in the other cohorts. The percentage of days where medication was available during the observation period was similar across all cohorts with the majority of patients having noted in the table. When considering the average total number of different prescribing specialists that patients might have seen during the 2-year period, the overall average was 4.5 specialists (SD 2.6) per patient ( Table 6 ). The NEURO group average was the highest at 4.9 (SD 2.7), followed by the OA group with 4.7 (SD 2.4), the NEURO/NOCI group with 4.4 (SD 2.6), and the NOCI group with 4.2 (SD 2.4). All pairwise tests were statistically significant (P < 0.0001).
Medication Use
Considering all types of medication claims observed among all cohorts, the overall mean prescription claim count per patient for the 2-year observation period was 57.9 claims (SD 56.2; Table 7 ). Across cohorts, the NEURO/NOCI cohort had the 
TABLE 5
Medical Providers 0% to <30% of days with pain medication availability. At least 1 prescription for a weak opioid was filled by the majority of patients (85.1%-88.2%). However, at least 1 opioid (weak or strong) in the observation year was an analysis inclusion criterion. When strong opioids are considered, at least 1 prescription for a strong opioid was filled by a greater percentage of patients with NEURO/NOCI (42.6%) or NEURO (39.0%) diagnoses than patients with NOCI (29.6%) or OA (38.0%) diagnoses (data not shown on graph). Combination treatment, defined as claims for more than 1 pain medication of any type (i.e., within or between WHO ladder steps), was observed in more than half (54.5%) of OA patients, with NEURO/NOCI, NEURO, and NOCI patients following at 53.3%, 44.5%, and 38.9%, respectively (data not shown).
Antidepressants, anticonvulsants, muscle relaxants, and steroids were common treatments and were available to approximately 26.2%, 11.1%, and 10.6% of patients, respectively, during the observation period (Figure 3) . Patients in the NEURO/NOCI group had greater availability of adjunct medications. This research also identified the subset of medications within these classes that have been described in the literature as being used as adjuvant treatments for pain. Almost all of the drugs within the muscle relaxant and steroid classes are used specifically for pain. There was less certainty with the antidepressant and anticonvulsant classes for pain. Therefore, statistics are shown for both the overall class as well as for the subset typically used for pain relief. The NEURO/NOCI cohort had the greatest percentage of patients using adjunctive medications from each class (antidepressants 41.5%; anticonvulsants 28.0%; muscle relaxants 46.1%; and steroids 38.1%) compared with the other cohorts, with the use of muscle relaxants being most common. A substantial percentage of patients in all of the cohorts had antidepressant use (range from 32.8% to 41.5%), with approximately half having an antidepressant typically associated with pain relief (tricyclics and serotonin-norepinephrine reuptake inhibitors [SNRI] 
Potential Drug Interactions of the Cytochrome P450 Pathway
Considering all cohorts, 32.2% of patients had 10 or more days of overlapping drug availability (of inducers or inhibitors of cytochrome P450 used concomitantly; Table 8 ). The NEURO/NOCI cohort showed the highest potential for drug interactions, with 38.4% of patients having 10 or more days of overlapping drug availability. The OA, NEURO, and NOCI cohorts followed with 33.4%, 32.3%, and 26.1%, respectively. All pairwise comparisons between cohorts were significantly different at P < 0.0001 with the exception of NEURO versus OA, which was P = 0.3342.
Adjuvant Procedures
According to coding from the Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology (CPT), chiropractic and physical therapies were the most frequently billed coded claims for services among all cohorts except OA patients ( Table 9 ). The NEURO/NOCI and NOCI cohorts used these adjuvant services to a much larger extent than the other cohorts. The most commonly used services among all cohorts included chiropractic therapy, physical therapy, and TENS (bioelectric therapy), but there was variability among services by cohort. Most statistical tests for differences among the cohorts were significant with a few exceptions. Pairwise tests showed the following tests that were not significant at P < 0.05: physical therapy for NOCI versus OA; psychological therapy for NEURO versus NOCI; neuromuscular re-education for NEURO versus NOCI and OA; neuromuscular re-education for NOCI versus OA; spinal cord stimulation for NEURO versus NOCI and NOCI versus OA; and intrathecal pump implant for NOCI versus OA. All other pairwise differences were significant at P < 0.05.
■■ Discussion
This assessment provided insights into the challenges physicians face when treating patients presenting with pain. Treatment challenges are complex and encompass patient characteristics (e.g., concomitant illnesses), provider issues (e.g., multiple physician involvement), treatment choices (e.g., types of pain and adjuvants medications used), and treatment consequences (e.g., the potential for drug interactions). 
Nonspecific drugs within class
Specific drugs within class that are more typically used for pain 
FIGURE 2

Percentage of Patients with WHO Pain Medication by Type of Medication and Frequency of Availability Category
A large percentage of patients had comorbid conditions. For example, hypertension, a chronic condition frequently requiring lifetime medication treatment, was observed in 36%-61% of the cohorts, with the highest percentage observed in the OA group. These results are consistent with those reported by Gore et al., 10 who used claims data from managed care health plans to assess comorbidities and resource use among OA patients. Rates of comorbid hypertension, hyperlipidemia, and coronary heart disease reported by Gore et al. were 54.4%, 52.1%, and 10.6%, respectively. The average age of the Gore et al. analysis population was 56.9 years. In the current analysis, the average age of the OA cohort was 53.6, and hypertension, hyperlipidemia, and coronary heart disease observed in the OA cohort were somewhat higher than those reported by Gore et al., at 61.2%, 59.5%, and 11.5%, respectively. The non-OA cohorts in our analysis had comparable cardiovascular comorbidity rates, except that hypertension among the NOCI cohort was lower, at 35.6%. Concomitant rates of depression (12.4%), anxiety (8.6%), and sleep disorders (11.9%) observed by Gore et al. were somewhat lower than reported here (16.5%, 10.7%, 18.9%). Many patients with a comorbid illness will require chronic medication use. Physicians treating patients presenting with pain need to identify medications used for comorbid illnesses to guard against adverse effects and drug interactions.
This analysis further demonstrated that multiple providers were involved in treating the various pain cohorts. In the current analysis, the mean number of prescribing physicians per patient was 4.5 over a 2-year period. Visiting multiple physicians would not be unexpected behavior when chronic illnesses are involved and likely reflects the need for specialists' care. For example, the mean number of specialists visited by the NEURO group was 4.9 during the 2-year period. The n % a n % a n % a n % a n % a 27,358 32 In terms of treatment choices, weak opioids accounted for most of the pain medication claims used by all cohorts. However, many nonopioids are available without a prescription and may not appear in a paid claims database. The percentage of patients using nonopioids is likely to be an underrepresentation. The mean number of pain-related prescriptions was 8.8 per person over the 2-year period. (The prescription count did not represent consecutive months of treatment but claims that could have occurred at any time during the 2-year period.) This number is more likely indicative of acute pain treatment rather than chronic pain treatment. Chronic pain treatment would have likely resulted in more prescription claims for strong opioids. 12, 13 Strong opioid prescriptions are not refillable and require a new prescription each month; therefore, a higher mean for pain-related prescriptions would be expected for chronic treatment.
Prior research has shown that adequate pain control often requires multiple medications. [14] [15] [16] In this analysis, overlapping or simultaneous prescriptions for multiple pain medications were observed in more than half (54.5%) of OA patients, with the NEURO/NOCI, NEURO, and NOCI groups following at 53.3%, 44.5%, and 38.9%, respectively. The use of simultaneous medications or perhaps combination therapy might indicate that the primary pain medications were not sufficient as monotherapy for pain relief. A report by RomanÒ et al. (2012), 17 discussing the treatment of low back pain, compared monotherapy with combination therapy or placebo for the treatment of low back pain and concluded that monotherapy is often only partially effective treatment and that combining drugs with different mechanisms of action might be a rational approach because of the different mechanisms that cause low back pain. Therefore, combination drug treatment for pain is likely to occur but adds another medication to the patient's overall treatment regimen. Combination therapy may also represent use of multiple opioids. For example, patients could be combining a long-acting opioid with a short-acting opioid for breakthrough pain.
In addition to simultaneous treatment with traditional pain medications, claims for adjuvant treatments including antidepressants, anticonvulsants, muscle relaxants, and steroids were observed in this analysis. The mean number of adjuvant claims was 12.7 per person over the 2-year period. These results are consistent with the report of Bair and Sanderson (2011) 18 from a comprehensive literature review of co-analgesics or adjuvant analgesics. The Bair and Sanderson analysis stated that antidepressants (particularly the SNRIs duloxetine and milnacipran), anticonvulsants, skeletal muscle relaxants, topical analgesics, and antispasmodic agents are often used as co-analgesics. According to Bair and Sanderson, the rationale for adjuvant use includes enhancing the effect of opioid analgesics or NSAIDs, providing independent analgesic activity in certain painful conditions, or counteracting the adverse effects of some analgesics. Thus, adjuvant medications are commonly found along with those indicated specifically for pain.
Given the number of prescriptions and concomitant health conditions observed in the pain cohorts, a drug interaction assessment was included to demonstrate the likelihood of interactions among medications. The cytochrome P450 interaction was used because the drugs listed in the claims data could be categorized as inhibitors or inducers of the cytochrome P450 pathway. The results showed that 25.7% of patients had 10 or more days of overlapping drug availability (of inducers or inhibitors of cytochrome P450 used concomitantly). These types of drug-drug exposures have the potential to cause significant pharmacokinetic interactions. Using a claims database of patients taking opioid analgesics, Summers et al. (2011) 19 assessed the economic impact of incident drug-drug exposures (DDEs) with the potential to cause pharmacokinetic drug-drug interactions (DDIs). The Summers et al. analysis reported that drug-drug exposures were relatively common among subjects. Furthermore, health care costs 6 months after the DDE were significantly higher in subjects with DDE versus matched subjects without DDE, providing evidence that drug-drug interactions impact health care costs.
Limitations
As with any claims-based analysis, this analysis may be limited by any coding errors that could have resulted in the misclassification of patients and other variables. Regarding adjunct medications such as antidepressants, there was no information available to verify whether the adjunct medications were used for pain or comorbidities. The claims database does not make it possible to associate prescription claims with diagnoses. Also, the database does not provide a direct link to the provider type who wrote the prescription that appears in the claims data. Several of the analyses presented claim counts. No evaluation of duration of therapy was performed for the adjuvant medications. The DDIs presented in this analysis represented potential interactions. Use of an administrative claims database provides information about drugs that were dispensed; however, there was no way to verify whether the drugs were actually taken simultaneously other than observing overlapping days of supplies. Medications that do not require a prescription are likely to be underrepresented in this analysis. The medications used for this interaction analysis were a selected list of pain-related therapies. Use of a more comprehensive list of all drugs that were actually dispensed would likely detect more potential interactions. Furthermore, the DDI analysis is exploratory in nature, and no evaluation of the seriousness of the interactions was performed. This analysis did not include cohorts with nonpain-related diagnoses. No commentary can be provided on how patients with pain-related diagnoses compare with patients without pain-related diagnoses.
■■ Conclusions
Treatment of patients with pain-related complaints is complex and further complicated by the existence of concomitant illnesses and treatment by multiple specialists. Choosing the appropriate pain treatment involves assessing currently used medications for existing illnesses and deciding on the appropriate types of pain medications. Use of combination and adjuvant prescription medications may be desirable to optimize efficacy. However, potentially serious drug-drug interactions are a consequence of multiple drug use and require thoughtful consideration by those involved in patient care. 
